MILAN -- The combination of carboplatin and paclitaxel retained its position as the first-line standard for patients with ovarian cancer, fending off a challenge by pegylated liposomal doxorubicin (PLD, Doxil) added to carboplatin.
MILAN -- The combination of carboplatin and paclitaxel retained its position as the first-line standard for patients with ovarian cancer, fending off a challenge by pegylated liposomal doxorubicin (PLD, Doxil) added to carboplatin.
